Cogstate Schizophrenia Battery

Assess cognitive function in subjects with schizophrenia in both the acute and chronic stages.

Cogstate’s computerised battery of rapid, reliable, simple and sensitive tests measures the cognitive domains affected by schizophrenia: processing speed, attention, verbal and visual learning, working memory, visual motor function, executive function and social cognition.

Tests can be grouped to match the cognitive domains recommended by the MATRICS group, or smaller groups of tests can be assembled to measure more specific domains. For each test, the construct validity for cognitive impairment in schizophrenia, as well as the sensitivity to change in cognition in schizophrenia has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical populations and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

Detection Test

The Detection test measures processing speed using a simple reaction time paradigm.

Learn More

Identification Test

The Identification test measures attention using a choice reaction time paradigm.

Learn More

One Card Learning Test

The One Card Learning test measures visual memory using a pattern separation paradigm.

Learn More

One Back Test

The One Back test measures working memory using an n-back paradigm.

Learn More

Two Back Test

The Two Back test measures working memory using an n-back paradigm.

Learn More

International Shopping List Test

The International Shopping List Test measures verbal learning using a word list learning paradigm.

Learn More

Social-Emotional Cognition Test

The Social-Emotional Cognition Test measures emotional recognition using an odd-man out paradigm.

Learn More

Groton Maze Learning Test

The Groton Maze Learning Test measures executive function using a maze learning paradigm.

Learn More

Battery Details

Length:Approx. 35 minutes
(if all tests in the battery are selected*)
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Learn More About Computerized Assessment

Key References

Bartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., Detore, N. R., Altshuler, L. L., …  Nuechterlein, K. H. (2011). Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophrenia Research, 132(1), 35-41. doi: 10.1016/j.schres.2011.06.029

Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R.,  Seoane, F., Beaver, J. S.,  Duan, N. & Hosford, D. A., (2013) A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia. Neuropsychopharmacology, 38, 968-975.

Pietrzak, R. H., Snyder, P. , J.Maruff, P. (2010)  Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology, 25, 353-358.

Preskorn, S. H., Gawryl, M., Dgetluck, N., Palfreyman, M., Bauer, L. O., & Hilt, D. C. (2014). Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. Journal of Psychiatric Practice, 20(1), 12–24. doi:10.1097/01.pra.0000442935.15833.c5

Riedel, M., Schmitz, M., Kåre, P., Ferrannini, L., Franco, M. A., Alfano, V., & Dencker, E. (2015). Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance , sedation and patient satisfaction in patients with schizophrenia : A randomised , double-blind , crossover study ( eXtRa ). Schizophrenia Research. doi:10.1016/j.schres.2014.12.027